Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology

Cancers

Volumn 2, Issue 4, 2010, Pages 1830-1837

  Verma, Mukesh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Cancer; Diagnosis; Epidemiology; Epigenetics; Glycans; Methylation index; Pancreas; Prognosis; Sensitivity; Specificity; Survival; Treatment

Indexed keywords

BIOLOGICAL MARKER; K RAS PROTEIN; MESSENGER RNA; MICRORNA; NEURTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ONCOPROTEIN; PROTEIN DKK3; PROTEIN NPTX2; PROTEIN P16; PROTEIN PPENK; PROTEIN REG4; RAS PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 2; SERINE PROTEINASE; SERINE PROTEINASE 2; SOMATOMEDIN; TROPHOBLAST CELL SURFACE ANTIGEN; UNCLASSIFIED DRUG;

CANCER SCREENING; DISEASE MARKER; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; PANCREAS CANCER; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952257911     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2041830     Document Type: Review

References (43)

1. Grote, T.; Logsdon, C.D. Progress on molecular markers of pancreatic cancer. Curr. Opin. Gastroenterol. 2007, 23, 508-514.
2. Morse, D.L.; Balagurunathan, Y.; Hostetter, G.; Trissal, M.; Tafreshi, N.K.; Burke, N.; Lloyd, M.; Enkemann, S.; Coppola, D.; Hruby, V.J.; Gillies, R.J.; Han, H. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem. Pharm. 2010, 80, 748-754.
3. Verma, M. Pancreatic cancer epidemiology. Tech. Cancer Res. Treat. 2005, 4, 295-301.
4. Bartosch-Härlid, A.; Andersson, R. Diabetes Mellitus in Pancreatic Cancer and the Need for Diagnosis of Asymptomatic Disease. Pancreatology 2010, 10, 423-428.
5. Richards, N.G.; Rittenhouse, D.W.; Freydin, B.; Cozzitorto, J.A.; Grenda, D.; Rui, H.; Gonye, G.; Kennedy, E.P.; Yeo, C.J.; Brody, J.R.; Witkiewicz, A.K. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg. 2010, 252, 499-505.
6. Takayama, R.; Nakagawa, H.; Sawaki, A.; Mizuno, N.; Kawai, H.; Tajika, M.; Yatabe, Y.; Matsuo, K.; Uehara, R.; Ono, K.-I.; Nakamura, Y.; Yamao, K. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J. Gastroenterol. 2010, 45, 52-59.
7. Stolzenberg-Solomon, R.Z.; Weinstein, S.; Pollak, M.; Tao, Y.; Taylor, P.R.; Virtamo, J.; Albanes, D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am. J. Epidemiol. 2008, 168, 1047-1055.
8. Verma, M.; Manne, U. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit. Rev. Onc./Hemt. 2006, 60, 9-18.
9. Verma, M. Proteomics and cancer epidemiology. Meth. Mol. Biol. 2009, 471, 197-215.
10. Verma, M.; Seminara, D.; Arena, F.J.; John, C.; Iwamoto, K.; Hartmuller, V. Genetic and epigenetic biomarkers in cancer: Improving diagnosis, risk assessment, and disease stratification. Mol. Diagn. Ther. 2006, 10, 1-15.
11. Jiang, Y.; MacKley, H.; Cheng, H.; Ajani, J.A. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark. Med. 2010, 4, 535-541.
12. Kriegshuser, G.; Auner, V.; Zeillinger, R. New and potential clinical applications of KRAS as a cancer biomarker. Exp. Opin. Med. Diagn. 2010, 4, 383-395.
13. M. Biomarkers for risk assessment in molecular epidemiology of cancer. Tech. Cancer Res. Treat. 2004, 3, 505-514.
14. Banerjee, H.N.; Verma, M. Epigenetic mechanisms in cancer. Biomark. Med. 2009, 3, 397-410.
15. Hwang, J.H.; Voortman, J.; Giovannetti, E.; Steinberg, S.M.; Leon, L.G.; Kim, Y.T.; Funel, N.; Park, J.K.; Kim, M.A.; Kang, G.H.; Kim, S.W.; Del Chiaro, M.; Peters, G.J.; Giaccone, G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010, 5, 1-12.
16. Kong, X.; Du, Y.; Wang, G.; Gao, J.; Gong, Y.; Li, L.; Zhang, Z.; Zhu, J.; Jing, Q.; Qin, Y.; Li, Z. Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis. Dig. Dis. Sci. 2010, 10, 1-8.
17. Ho, A.S.; Huang, X.; Cao, H.; Christman-Skieller, C.; Bennewith, K.; Le, Q.-T.; Koong, A.C. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3, 109-113.
18. Chen, R.; Pan, S.; Aebersold, R.; Brentnall, T.A. Proteomics studies of pancreatic cancer. Proteomics Clin. Appl. 2007, 1, 1582-1591.
19. Hanas, J.S.; Hocker, J.R.; Cheung, J.Y.; Larabee, J.L.; Lerner, M.R.; Lightfoot, S.A.; Morgan, D.L.; Denson, K.D.; Prejeant, K.C.; Gusev, Y.; Smith, B.J.; Hanas, R.J.; Postier, R.G.; Brackett, D.J. Biomarker identification in human pancreatic cancer sera. Pancreas 2008, 36, 61-69.
20. Mori-Iwamoto, S.; Kuramitsu, Y.; Ryozawa, S.; Mikuria, K.; Fujimoto, M.; Maehara, S.; Maehara, Y.; Okita, K.; Nakamura, K.; Sakaida, I. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 2007, 31, 1345-1350.
21. Douglas, J.B.; Silverman, D.T.; Pollak, M.N.; Tao, Y.; Soliman, A.S.; Stolzenberg-Solomon, R.Z. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomark. Prev. 2010, 19, 2298-2306.
22. Chen, R.; Pan, S.; Duan, X.; Nelson, B.H.; Sahota, R.A.; de Rham, S.; Kozarek, R.A.; McIntosh, M.; Brentnall, T.A. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol. Cancer 2010, 9, 149-151.
23. Sitek, B.; Sipos, B.; Alkatout, I.; Poschmann, G.; Stephan, C.; Schulenborg, T.; Marcus, K.; Lüttges, J.; Dittert, D. D.; Baretton, G.; Schmiegel, W.; Hahn, S. A.; Klöppel, G.; Meyer, H. E.; Stühler, K. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J. Proteome Res. 2009, 8, 1647-1656.
24. Gao, J.; Zhu, F.; Lv, S.; Li, Z.; Ling, Z.; Gong, Y.; Jie, C.; Ma, L. Identification of pancreatic juice proteins as biomarkers of pancreatic cancer. Oncol. Rep. 2010, 23, 1683-1692.
25. Dive, C.; Smith, R.A.; Garner, E.; Ward, T.; George-Smith, S.S.; Campbell, F.; Greenhalf, W.; Ghaneh, P.; Neoptolemos, J.P. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br. J. Cancer 2010, 102, 577-582.
26. Tonack, S.; Aspinall-O'Dea, M.; Jenkins, R.E.; Elliot, V.; Murray, S.; Lane, C.S.; Kitteringham, N.R.; Neoptolemos, J.P.; Costello, E. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J. Proteomics 2009a, 73, 352-356.
27. Elghazawy, R.M.; Verbeke, C.S. Pathology of pancreatic tumors. Surgery 2010, 28, 189-197.
28. Hayes, G.M.; Carrigan, P.E.; Dong, M.; Reubi, J.; Miller, L.J. A Novel Secretin Receptor Splice Variant Potentially Useful for Early Diagnosis of Pancreatic Carcinoma. Gastroenterology 2007, 133, 853-861.
29. Hartel, M.; Narla, G.; Wente, M.N.; Giese, N.A.; Martignoni, M.E.; Martignetti, J.A.; Friess, H.; Friedman, S.L. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur. J. Cancer 2008, 44, 1895-1903.
30. Omenn, G.S.; Yocum, A.K.; Menon, R. Alternative splice variants, a new class of protein cancer biomarker candidates: Findings in pancreatic cancer and breast cancer with systems biology implications. Dis. Markers 2010, 28, 241-251.
31. Sabbaghian, M.S.; Rothberger, G.; Alongi, A.P.; Gagner, J.-P.; Goldberg, J.D.; Rolnitzky, L.; Chiriboga, L.; Hajdu, C.H.; Zagzag, D.; Basch, R.; Shamamian, P. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Res. 2010, 30, 2911-2917.
32. Zhang, L.; Farrell, J.J.; Zhou, H.; Elashoff, D.; Akin, D.; Park, N.; Chia, D.; Wong, D.T. Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer. Gastroenterology 2010, 138, 949-957.
33. Haug, U.; Wente, M.N.; Seiler, C.M.; Jesnowski, R.; Brenner, H. Stool testing for the early detection of pancreatic cancer: Rationale and current evidence. Exp. Rev. Mol. Diagn. 2008, 8, 753-759.
34. Gold, D.V.; Karanjawala, Z.; Modrak, D.E.; Goldenberg, D.M.; Hruban, R.H. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res. 2007, 13, 7380-7387.
35. Tonack, S.; Aspinall-O'Dea, M.; Neoptolemos, J.P.; Costello, E. Pancreatic cancer: Proteomic approaches to a challenging disease. Pancreatology 2009b, 9, 567-576.
36. Anderson, M.A.; Brenner, D.E.; Scheiman, J.M.; Simeone, D.M.; Singh, N.; Sikora, M.J.; Zhao, L.; Mertens, A.N.; Rae, J.M. Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: Effect of amplicon length and quality assessment. J. Mol. Diagn. 2010, 12, 566-575.
37. Oliveira-Cunha, M.; Siriwardena, A.K.; Byers, R. Molecular diagnosis in pancreatic cancer. Diagn. Histopathol. 2008, 14, 214-222.
38. Laiyemo, A.O.; Kamangar, F.; Marcus, P.M.; Taylor, P.R.; Virtamo, J.; Albanes, D.; Stolzenberg-Solomon, R.Z. Serum pepsinogen level, atrophic gastritis and the risk of incident pancreatic cancer-A prospective cohort study. Cancer Epidemiol. 2009, 33, 368-373.
39. Fong, D.; Moser, P.; Krammel, C.; Gostner, J.M.; Margreiter, R.; Mitterer, M.; Gastl, G.; Spizzo, G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br. J. Cancer. 2008, 99, 1290-1295.
40. Melnik, M.K.; Webb, C.P.; Richardson, P.J.; Luttenton, C.R.; Campbell, A.D.; Monroe, T.J.; O'Rourke, T.J.; Yost, K.J.; Szczepanek, C.M.; Bassett, M.R.; Truszkowski, K.J.; Stein, P.; Van Brocklin, M.W.; Davis, A.T.; Bedolla, G.; Vande Woude, G.F.; Koo, H.-M. Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer. Mol. Cancer Therap. 2010, 9, 2423-2429.
41. Garrido-Laguna, I.; Tan, A.C.; Uson, M.; Angenendt, M.; Ma, W.W.; Villaroel, M.C.; Zhao, M.; Rajeshkumar, N.V.; Jimeno, A.; Donehower, R.; Iacobuzio-Donahue, C.; Barrett, M.; Rudek, M.A.; Rubio-Viqueira, B.; Laheru, D.; Hidalgo, M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer 2010, 103, 649-655.
42. Reni, M. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J. Gastroenterol. 2010, 16, 4883-4887.
43. Teutsch, S.M.; Bradley, L.A.; Palomaki, G.E.; Haddow, J.E.; Piper, M.; Calonge, N.; Dotson, W.D.; Douglas, M.P.; Berg, A.O.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet. Med. 2009, 11, 3-14.